Secretory Carcinoma of the Thyroid Gland: Report of a Highly Aggressive Case Clinically Mimicking Undifferentiated Carcinoma and Review of the Literature
- 217 Downloads
- 1 Citations
Abstract
After being described in the salivary glands as a malignancy with features essentially identical to those of the breast, secretory carcinoma (SC) (formerly mammary analogue SC) has now been identified in other sites including the skin, lung, and thyroid gland. In the breast, SC has a relatively favorable prognosis. Likewise when arising in the salivary glands, it is generally considered to be a low to intermediate grade carcinoma; however, there is a range of clinical behavior with occasional patients dying of progressive disease. SCs of the thyroid gland are rare, and reports suggest a relatively aggressive behavior, at least relative to well differentiated carcinomas such as papillary carcinoma and minimally invasive follicular carcinoma. We present a patient with a highly aggressive thyroid gland SC that mimicked undifferentiated carcinoma clinically. The patient had widespread metastatic disease and died rapidly from airway compromise. We also review the literature for reported cases of thyroid gland SC in order to better establish the clinical features and expected clinical course of such tumors occurring at this site.
Keywords
Mammary analogue secretory carcinoma Thyroid ETV6 gene rearrangement Papillary carcinoma Anaplastic carcinomaNotes
Compliance with Ethical Standards
Conflict of interest
The authors report that there are no conflicts of interest to disclose.
References
- 1.Lakhani SR, Ellis IO, Schnitt SJ, WHO classification of tumours of the breast. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2012.Google Scholar
- 2.McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA. 1966;195:388.CrossRefGoogle Scholar
- 3.Tavassoli FA, Norris HJ. Secretory carcinoma of the breast. Cancer. 1980;45:2404–13.CrossRefGoogle Scholar
- 4.Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med. 2011;135:1606–10.CrossRefGoogle Scholar
- 5.Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608.PubMedGoogle Scholar
- 6.Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11:55–67.CrossRefGoogle Scholar
- 7.El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. WHO classification of head and neck tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2017.Google Scholar
- 8.Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012;61:387–94.CrossRefGoogle Scholar
- 9.Skálová A, Vanecek T, Majewska H, Laco J, Grossman P, Simpson RH, et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 2014;38:23–33.CrossRefGoogle Scholar
- 10.Bishop JA, Taube JM, Su A, Binder SW, Kaxakov DV, Michal M, et al. Secretory carcinoma of the skin harboring ETV6 gene fusions: a cutaneous analogue to secretory carcinomas of the breast and salivary glands. Am J Surg Pathol. 2017;41:62–6.CrossRefGoogle Scholar
- 11.Hyrcza MD, Ng T, Crawford RI. Detection of the ETV6-NTRK3 translocation in cutaneous mammary-analogue secretory carcinoma. Diagn Histopathol. 2015;21:481–84.CrossRefGoogle Scholar
- 12.Huang T, McHugh JB, Berry GJ, Myers JL. Primary mammary analogue secretory carcinoma of the lung: a case report. Hum Pathol. 2018;74:109–13.CrossRefGoogle Scholar
- 13.Nguyen JK, Bridge JA, Joshi C, McKenney JK. Primary mammary analog secretory carcinoma (MASC) of the vulva with ETV6-NTRK3 fusion: a case report. Int J Gynecol Pathol. 2018.Google Scholar
- 14.Baneckova M, Agaimy A, Andreasen S, Vanecek T, Steiner P, Slouka D, et al. Mammary analog secretory carcinoma of the nasal cavity: characterization of 2 cases and their distinction from other low-grad sinonasal adenocarcinomas. Am J Surg Pathol. 2018;42:735–43.CrossRefGoogle Scholar
- 15.Lurquin E, Jorissen M, Debiec-Rychter M, Hermans R, Hauben E. Mammary analogue secretory carcinoma of the sinus ethmoidalis. Histopathology. 2015;67:749–51.CrossRefGoogle Scholar
- 16.Stevens TM, Kovalovsky AO, Velosa C, Shi Q, Dai Q, Owen RP, et al. Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol. 2015;2864:1084–100.CrossRefGoogle Scholar
- 17.Reynolds S, Shaheen M, Olson G, Barry M, Wu J, Bocklage T. A case of primary mammary analog secretory carcinoma (MASC) of the thyroid masquerading as papillary thyroid carcinoma: potentially more than a one off. Head Neck Pathol. 2016;10:405–13.CrossRefGoogle Scholar
- 18.Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, et al. Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol. 2016;29:985–95.CrossRefGoogle Scholar
- 19.Dettloff J, Seethala RR, Stevens TM, Brandwein-Gensler M, Centeno BA, Otto K, et al. Mammary analog secretory carcinoma (MASC) involving the thyroid gland: a report of the first 3 cases. Head Neck Pathol. 2016;11:124–30.CrossRefGoogle Scholar
- 20.Rupp AP, Bocklage TJ. Mammary analog secretory carcinoma of thyroid: a case report. Diagn Cytopathol. 2017;45:45–50.CrossRefGoogle Scholar
- 21.Lei Y, Chiosea SI. Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. Head Neck Pathol. 2012;6:166–70.CrossRefGoogle Scholar
- 22.Majewska H, Skálová A, Stodulski D, Klimkova A, Steiner P, Stankiewicz C, et al. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. Virchows Arch. 2015;466:245–54.CrossRefGoogle Scholar
- 23.Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21:350–3.CrossRefGoogle Scholar
- 24.Bishop JA, Taube JM, Su A, Binder SW, Kazakov DV, Michal M, et al. Secretory carcinoma of the skin harboring ETV6 gene fusions: a cutaneous analogue to secretory carcinomas of the breast and salivary glands. Am J Surg Pathol. 2017;41:62–6.CrossRefGoogle Scholar
- 25.Wu EY, Lebastchi J, Marqusee E, Lorch JH, Krane JF, Barletta JA. A case of primary secretory carcinoma of the thyroid with high-grade features. Histopathology. 2017;71:665–69.CrossRefGoogle Scholar
- 26.Liao H, Khan A, Miron PM, Cornejo KM. Mammary analogue secretory carcinoma of the thyroid mimicking locally advanced papillary thyroid carcinoma: a rare case report. Int J Surg Pathol. 2018;26:459–63.CrossRefGoogle Scholar
- 27.Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, et al. Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope. 2014;124:188–95.CrossRefGoogle Scholar
- 28.Khalele BA. Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. Head Neck. 2017;39:1243–48.CrossRefGoogle Scholar
- 29.Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013;7:35–9.CrossRefGoogle Scholar
- 30.Simpson RHW, Bacani J, Skalova A. (2018) United States and Canadian Academy of Pathology evening speciality conference—head, neck, & endocrine pathology. In: Evening speciality conference: challenging cases and concepts in head and neck and endocrine pathology. Vancouver, BC, Canada.Google Scholar
- 31.Krausz T, Jenkins D, Grontoft O, Pollock DJ, Azzopardi JG. Secretory carcinoma of the breast in adults: emphasis on late recurrence and metastasis. Histopathology. 1989;14:25–36.CrossRefGoogle Scholar
- 32.Kralik JM, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011;6:19.CrossRefGoogle Scholar
- 33.Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–76.CrossRefGoogle Scholar
- 34.Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sata Y, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999;93:1355–63.CrossRefGoogle Scholar
- 35.Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, Kozakewich HP, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451–8.CrossRefGoogle Scholar
- 36.Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–7.CrossRefGoogle Scholar
- 37.Seethala RR, Chiosea SI, Liu CZ, et al. Clinical and morphologic features of ETV6-NTRK3 translocated papillary thyroid carcinoma in an adult population without radiation exposure. Am J Surg Pathol. 2016;41:446–57.CrossRefGoogle Scholar
- 38.Ito Y, Ishibashi K, Masaki A, Fujii K, Fujiyoshi Y, Hattori H, et al. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. Am J Surg Pathol. 2015;39:602–10.CrossRefGoogle Scholar
- 39.Skálová A, Vanecek T, Simpson RH, Laco J, Majewska H, Baneckova M, et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol. 2016;40:3–13.CrossRefGoogle Scholar
- 40.Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016. https://doi.org/10.1002/cncr.29887.CrossRefPubMedGoogle Scholar
- 41.Otsubo R, Mussazhanova Z, Akazawa Y, et al. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature. J Pediatr Endocrinol Metab. 2018;31:461–7.CrossRefGoogle Scholar
- 42.Skalova A, Vanecek T, Martinek P, Weinreb I, Stevens TM, Simpson RHW, et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol. 2018;42:234–46.CrossRefGoogle Scholar
- 43.Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27:920–6.CrossRefGoogle Scholar